<DOC>
	<DOC>NCT00657904</DOC>
	<brief_summary>The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.</brief_summary>
	<brief_title>Bicalutamide (Casodexâ„¢) Versus Placebo in Patients With Early Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Prostate cancer in the early stage of disease Prostate removed and/or radiation therapy to the prostate area Previous systemic therapy for prostate cancer Previous history of another form of cancer (not prostate) within 5 years of study start.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>androgen antagonists</keyword>
	<keyword>prostate neoplasms</keyword>
</DOC>